PBS Pharmaceuticals in Hospitals Review

20 May 2019 - The Department of Health completed the PBS Pharmaceuticals in Hospitals Review to better understand how PBS medicines ...

Read more →

Australia's GBMA launches hub for biosimilar education

13 May 2019 - In 2018, the Generic Biosimilar Medicines Association was awarded the Biosimilar Education Grant by the Australian government ...

Read more →

Biopharma CEOs explain problems with biosimilars to Congress

12 April 2019 - Following their Senate Finance Committee hearing in February, all seven biopharmaceutical CEOs have now offered hundreds ...

Read more →

Overprescribed: high cost isn’t America’s only drug problem

2 April 2019 - The pharmaceutical industry has followed a brilliant two-pronged strategy to maximize its profits: raise prices and ...

Read more →

Drug Utilisation Sub-Committee outcome statement

29 March 2019 - The outcome statement from the February 2019 Drug Utilisation Sub-Committee meeting is now available. ...

Read more →

19,000 Australians now using PBS subsidised anti-HIV drugs

25 March 2019 - About 19,000 Australians have taken advantage of anti-HIV drugs in the first two years of groundbreaking ...

Read more →

Lyrica, Pfizer, and how big pharma gets what it wants

23 March 2019 - In 2011, few had heard of Pfizer’s nerve-pain pill Lyrica. It was mostly confined to specialist ...

Read more →

Promoting biosimilars up to health plans, manufacturers, doctors, Gottlieb says

21 March 2019 - As he wraps up his final weeks as commissioner of the FDA, Scott Gottlieb, MD, talked about ...

Read more →

Biosimilar uptake drivers

5 February 2019 - Information about Government initiatives to encourage the use of biosimilars is now available on the PBS website.  ...

Read more →

Europe closer to biosimilar rule change, despite fierce resistance from pharma

18 January 2019 - EFPIA says it weakens IP commitment - supporters say it will boost exports. ...

Read more →

Canadian payer reports a successful switch to biosimilars

21 January 2019 - In 2018, Green Shield Canada launched its pilot Biosimilar Transition Program, through 3 plan sponsors, under which ...

Read more →

Samsung faces resistance from big pharma in the U.S.

11 January 2019 - Incumbent biologic drug makers use rebates and exclusive contracts to fend off competition from new entrants. ...

Read more →

Underuse of innovative medicines in Germany: A justification for government intervention?

6 December 2018 - The German market for innovative medicines is characterised by simultaneous underuse and overuse.  ...

Read more →

Novartis joins call asking FDA to stop biosimilar trash-talkers

17 November 2018 - Novartis has joined Pfizer in asking FDA to stop campaigns from branded drugmakers that the pharmas ...

Read more →

German health minister calls for faster adoption of biosimilar drugs

14 November 2018 - Germany’s health minister Jens Spahn has called for faster adoption of cheaper copies of biotech drugs ...

Read more →